Abstract: Many research studies are directed toward developing safe and efficient collagen-based biomaterials as carriers for drug delivery systems. This article presents a comparative study of the properties of new collagen sponges prepared and characterized by different methods intended for biomedical applications. The structural integrity is one of the main properties for a biomaterial in order for it to be easily removed from the treated area. Thus, the effect of combining a natural polymer such as collagen with an antimicrobial drug such as oxytetracycline or doxycycline and glutaraldehyde as the chemical cross-linking agent influences the cross-linking degree of the material, which is in direct relation to its resistance to collagenase digestion, the drug kinetic release profile, and in vitro biocompatibility. The enzymatic degradation results identified oxytetracycline as the best inhibitor of collagenase when the collagen sponge was cross-linked with 0.5% glutaraldehyde. The drug release kinetics revealed an extended release of the antibiotic for oxytetracycline-loaded collagen sponges compared with doxycycline-loaded collagen sponges. Considering the behavior of differently prepared sponges, the collagen sponge with oxytetracycline and 0.5% glutaraldehyde could represent a viable polymeric support for the prevention/treatment of infections at the application site, favoring tissue regeneration.

Keywords: collagen; oxytetracycline; doxycycline; drug release; antimicrobial susceptibility; MTT test

1. Introduction

Antimicrobial resistance has become a major problem in recent years, and many studies in medicine are focused on this topic. Antibiotics are used both in human and veterinary therapies for infections reduction, and therefore, the role of resistance monitoring is very important [1,2]. Oxytetracycline hydrochloride (OTC) was discovered in the 1940, and was the first member of the tetracycline group [3]. The other tetracyclines were identified later, such as doxycycline hydrochloride (DXC) [4], which came into human pharmacological use in 1967. Due to their broad spectrum of action, OTC and DXC (Figure 1) are antimicrobial substances with bacteriostatic activity that are indicated for the treatment of some infections caused by Gram-negative and Gram-positive microorganisms [5]. OTC inhibits collagenase, preventing the collagen destruction that occurs at the marginal periodontium,
and which also inhibits alveolar bone resorption while having an antibacterial effect. Generally, tetracyclines are effective against most spirochetes and anaerobic bacteria; this action is relevant in terms of periodontitis [6–9].

![Chemical structure](image)

**Figure 1.** Chemical structure: (a) oxytetracycline hydrochloride; (b) doxycycline hydrochloride.

Considerable attention has focused on the development of drug delivery systems, and this is expected to continue in the future. Drug delivery is a method that is used in the administration of pharmaceutical compounds to achieve a therapeutic effect [10–12]. One of the most common approaches to achieve controlled release is to load a drug in a hydrophobic or hydrophilic matrix in order to accelerate or decrease the drug release, depending on the final applications. To obtain a reliable and efficient matrix-based delivery system, many aspects such as biocompatibility, polymers science, drug–matrix interactions, and drug physicochemical and therapeutic characteristics are required to merge together. An optimal drug delivery system can really have the desired benefit only if the drug is delivered at the targeted site and maintains performance for the proper duration.

A wide variety of materials classified in natural and synthesized biodegradable polymers have been used to develop delivery systems [13]. The first category includes collagen (CG) [14], gelatin, chitosan, and alginate, which are biocompatible and biodegradable. Collagen is a highly versatile material, and due to its well-established safety profile, it represents a favorable matrix to obtain carrier systems for the delivery of drugs, proteins, and genes [15–19], or generally to obtain composite scaffolds for bone tissue engineering [20,21]. Depending on the final therapeutic target, the collagen is treated by several methods such as physical [22], chemical [23,24] or enzymatic cross-linking [25–27]. Numerous methods related to the cross-linking of collagen-based biomaterials are described in the literature [28], with aldehydes such as glutaraldehyde (GA) and formaldehyde being widely used over the last decade. GA is a very reactive, available, and inexpensive chemical agent [29].

In our previous works, we successfully used glutaraldehyde as cross-linking agent for the collagen biomaterials processed in various forms (hydrogels, sponges) [11,21,24,30–33]. The physical–chemical, biopharmaceutical, and biological properties of the prepared drug-loaded collagen supports were improved in the presence of GA in terms of resistance to enzymatic degradation, goniometric characteristics, and morphological characteristics, ensuring at the same time controlled drug release profiles over several hours. Moreover, the designed carriers have maintained the integrity and the preservation of the collagen triple helix, and also have ensured the support viability and proliferation of different tested culture cells. Thus, even glutaraldehyde is contested as being a toxic cross-linking agent; we proved in our previous studies about collagen and doxycycline that GA is accepted by endothelial cells when it is used in small amounts [34].

The effect of the cross-linking agent and drug on the biostability of the treated biopolymeric material is very important [35]. Due to their intrinsic biodegradability, biomaterials are digested in body fluids. For the in vivo stability evaluation of the collagen-based biomaterials, the in vitro enzymatic degradation is studied. The collagen degradation process requires the presence of water and enzymes, and digestion of the bonds. By exposure to water, collagen swells, but complete collagen degradation occurs only when enzymes are involved. Very few enzymes are able to attack and degrade the triple helical structure of collagen. The enzymes that break down collagen into small peptides are called collagenases [36]. These enzymes have the ability to cleave collagen at physiological pH and
temperature. Collagenases are produced by bacteria such as *Clostridium hystolyticum*, *Pseudomonas aeruginosa*, *Bacteroides melanogenicus*, *Mycobacterium tuberculosis*, *Trichophyton schoenleinii*, and *Aspergillus oryzae*. Collagenase may simultaneously split each polypeptide chain across all three chains or attack at a single strand.

The collagen sponge morphological structure—pore size and porosity are two key important parameters, influencing the hydrophilicity, drug diffusion through the network, degradation properties, and interactions with cells. Collagen-doxycycline and collagen-minocycline cross-linked with glutaraldehyde sponges with different pore sizes were obtained by different temperatures of freezing during lyophilization, and the results showed that the sponges’ composition as well as their preparation process influenced the swelling behavior, the released drug percentage, and the porous architecture [37,38].

In this study, a therapeutic agent such as oxytetracycline or doxycycline is mixed in a polymeric matrix and treated with GA. As final products after a lyophilization process, sponges with different compositions were obtained and characterized by different experimental tools and techniques to establish the physicochemical characteristics. Additionally, the influence of matrix composition changes on drug release kinetics and biostability was evaluated. From the antimicrobial susceptibility point of view, antibiotic resistance of collagen matrix to *Escherichia coli*, *Staphylococcus aureus*, and *Enterococcus faecalis* was studied. Moreover, the effect of combining collagen with OTC or DXC on the enzymatic degradation and in vitro biocompatibility with dermal fibroblasts-type National Collection of Type Cultures (NCTC) was tested.

2. Materials and Methods

2.1. Materials and Preparation of Collagen Sponges

Collagen type I extracted from bovine skin was supplied by National Research & Development Institute for Textiles and Leather, Bucharest, Romania. The antimicrobial drugs oxytetracycline hydrochloride and doxycycline hydrochloride were purchased from Sigma Chemical Co. (Saint-Louis, MO, USA), and glutaraldehyde was used as the cross-linking agent and purchased from Merck (Darmstadt, Germany). For pH adjustment, 1 M of NaOH solution of analytical grade was used.

Collagen supports preparation, in the form of sponges, was based on a freeze-drying process [30] of homogenous mixtures containing CG, OTC, or DXC and GA. CG 1% with pH adjusted to 7.4 was mixed with a water solution of OTC or DXC 1 g/L for 30 min, and after another pH adjustment to 7.4, different concentrations of GA reported to dry CG and OTC or DXC substances were added and stirred for 10 min. The resultant mixtures were then freeze-dried. This process consists of three steps as follows: “Freezing” at −55 °C for 10 min, “Main drying” at 55 °C for 15 h, where ~90% of water is removed, and “Final drying” at 40 °C for 10 min. All the collagen sponges were packed in polyethylene bags and sterilized for 5 min on each side at 254 nm using a Vilber-Lourmat equipment.

The composition of the collagen sponges is shown in Table 1.

| Collagen Sponge | Gravimetric Ratio CG:OTC [w:w] | GA [%] |
|-----------------|-------------------------------|--------|
| CG:OTC:GA 0%    |                               | 0      |
| CG:OTC:GA 0.25% | 0.25                          | 0.50   |
| CG:OTC:GA 0.5%  | 1:0.1                         | 0.75   |
| CG:OTC:GA 1%    |                               | 1.00   |

Table 1. Composition of the CG–OTC and CG–DXC sponges with different GA concentrations. CG: collagen, DXC: doxycycline hydrochloride, GA: glutaraldehyde, OTC: oxytetracycline hydrochloride.
Table 1. Cont.

| Collagen Sponge | Gravimetric Ratio CG:DXC [w:w] | GA [%] |
|-----------------|--------------------------------|--------|
| CG:DXC:GA 0%    |                                | 0      |
| CG:DXC:GA 0.25% |                                | 0.25   |
| CG:DXC:GA 0.5%  | 1:0.1                          | 0.50   |
| CG:DXC:GA 0.75% |                                | 0.75   |
| CG:DXC:GA 1%    |                                | 1.00   |

2.2. Methods

Infrared spectroscopy (IR) measurements were performed using a Perkin Elmer Spectrum 100 FTIR spectrophotometer (Beaconsfield, UK) with a diamond ATR (attenuated total reflectance) device attached. The ATR-FTIR spectra were obtained over the domain of 4000–600 cm\(^{-1}\) at a spectral resolution of 4 cm\(^{-1}\). For each point, 16 scans were collected at 25 °C.

UV/Vis/NIR spectroscopy was performed on a Jasco UV/Vis/NIR spectrophotometer (Easton, MD, USA), model V 670. The spectra were recorded over the wavelength range of 200 to 2000 nm, with a step of 0.5 nm.

The swelling behavior of the collagen supports was evaluated by testing their ability to absorb water. The collagen sponges were cut into pieces of 0.5 × 0.5 cm and weighed before immersion in distilled water (\(W_i\)) for different periods of time up to 5 h at 25 °C. After that, the swollen collagen sponges were removed and weighed without dripping (\(W_f\)). The swelling capacity was calculated using Equation (1). Each test was averaged from three parallel measurements.

\[
\% S = \frac{w_f - w_i}{w_i} \times 100
\]  

(1)

The enzymatic degradation was carried out by exposing in vitro the collagen biomaterials to a collagen specific enzyme. Bacterial collagenase of *Clostridium histolyticum* from Sigma-Aldrich (Saint-Louis, MO, USA) and phosphate buffer solution (PBS) (pH 7.4) were used. To test the in vitro degradation, all the samples were cut into pieces of 0.5 × 0.5 cm, weighed before transfer in PBS (\(W_i\)), and incubated at 37 °C for 24 h. Then, collagenase (10 µg/mL) was embedded, and each sample was incubated again at 37 °C. At various time intervals (1 h, 2 h, 4 h, 8 h, 24 h, 48 h, 72 h, 96 h, and 168 h), the sponges were removed from the solution, squeezed, and weighed (\(W_t\)). The calculation of collagen degradation was performed as follows (Equation (2)):

\[
\% \text{collagen degradation} = \frac{w_i - w_t}{w_i} \times 100
\]  

(2)

Three samples were evaluated for each composition and the results of collagen degradation are expressed as mean values ± standard deviation.

Antimicrobial assay was tested against three main human pathogenic bacteria: Gram-negative bacterium, *Escherichia coli* ATCC 8738, respectively, Gram-positive bacteria, *Enterococcus faecalis* ATCC 29212 (facultative anaerobe), and *Staphylococcus aureus* ATTC 25923. The stock culture was maintained at 4 °C.

These strains were cultivated onto Luria–Bertani liquid medium (abbreviated “LB”) having the following composition: peptone (Merck, Darmstadt, Germany), 10 g/L; yeast extract (Biolife, Bucharest, Romania) 5 g/L, NaCl (Sigma-Aldrich, Saint-Louis, MO, USA) 5 g/L, and for bacto-agar (for plates, LBA, Sigma-Aldrich, Saint-Louis, MO, USA) 20 g/L agar (Fluka, Bucharest, Romania). LB was sterilized by autoclaving for 20 min at 15 psi (1.05 kg/cm\(^2\)) on liquid cycle.

The inhibition percentage of bacteria growth (as a measure of antibacterial activity) was calculated using the formula proposed by Jaiswal et al. in 2010 [39,40].
All the collagen samples evaluated for antibacterial activity were firstly sterilized with Vilber Lourmat equipment, Marne-la-Vallée, France.

Minimum bactericidal concentration (MBC) of oxytetracycline and doxycycline against the previously mentioned bacterial strains was determined using the broth dilution technique [41]. The MBC (defined as 100% killing) represents the lowest concentration of antibiotic that completely inhibited the bacteria growth. Serially diluted logarithmic concentrations of the antibiotic used, ranging from 400 µg/mL to 0.195 µg/mL, were inoculated with standardized overnight cultures of the bacteria and incubated at 37 °C for 18 h [42]. All the data were expressed as the mean ± standard deviation (SD) by measuring three independent replicates. Standard deviation was calculated as the square root of variance using the STDEV function in Excel 2010.

In vitro drug delivery from collagen sponges and kinetic analysis of the release data. The kinetic experiments were performed using a paddle dissolution equipment (Esadissolver, Milan, Italy) fitted with a sandwich device. The CG–OTC and CG–DXC sponges were placed on the sandwich device surface and immersed in phosphate buffer solution (pH 7.4). The release medium was maintained at 37 °C and continuously stirred at 50 rpm during the in vitro drug delivery evaluation. Samples of 5 mL were withdrawn from the release medium at specific time intervals over 10 h for CG–OTC sponges, and 8 h for CG–DXC sponges, respectively, and replaced by an equivalent volume of fresh, preheated phosphate buffer solution. The concentration of released antibiotic from the collagen sponges was monitored by UV-Vis spectrophotometry (Perkin Elmer UV-Vis Spectrophotometer, Überlingen, Germany) and determined from the standard curve obtained in the phosphate buffer solution pH 7.4, at wavelength of 363 nm for OTC (A_{1cm}^{1%} = 262, R^2 = 0.9993) and 348 nm for DXC (A_{1cm}^{1%} = 204, R^2 = 0.9979).

To analyze the antibiotics release kinetics from collagen sponges, the in vitro experimental data were fitted according to power law kinetic model (Equation (3)):

\[
\frac{m_t}{m_\infty} = k \times t^n,
\]

where \(m_t/m_\infty\) represents the fraction of drug released at time \(t\); \(k\)—the kinetic constant related to the characteristics of the drug delivery system expressed in 1/min^n; and \(n\)—the release exponent indicating the drug kinetic release mechanism [30]. Two particular cases of this equation could appear: (i) \(n = 0.5\) (Higuchi model) corresponding to a Fickian diffusion mechanism, the release being due to the drug diffusion, and (ii) \(n = 1\) indicating a zero-order kinetics, and the release involving the polymer relaxation. Values of \(n\) are associated with an anomalous drug transport mechanism, with different physicochemical processes being involved in the delivery process.

For measurements of cytotoxic activity, fragments of sponges were maintained for 24 h and 48 h respectively, in direct contact with the cell culture, followed by thiazolyl blue tetrazolium bromide (MTT) cytotoxicity test for both time intervals and by an optical microscopy examination of cell morphology after 48 h, as highlighted by hematoxylin–eosin staining. For testing the in vitro cytotoxicity of the sponges, dermal fibroblasts of mice cell line NCTC (clone 929) ECACC, Sigma-Aldrich were grown in a monolayer in minimum essential medium (MEM) with 10% fetal bovine serum (FBS) and 1% mixture of antibiotics (penicillin, streptomycin, and neomycin—PSN) were used. The cell culture, which was subcultured every three days, was kept under humid atmosphere with 5% CO\(_2\) at 37 °C. The experiment was performed in triplicate. Sponges with an area of 0.25 cm² (per 0.5 mL solution) were sterilized by UV radiation for 8 h.

Cells seeding was performed at a cell density of 4 × 10^4 cells/mL determined by the device type hemocytometer with a Carl Zeiss inverted microscope, Thornwood, NY, USA, and a Revco incubator operating at 37 °C, 5% CO\(_2\) in humid atmosphere. After an incubation time of 24 h, the culture medium was replaced by fresh culture medium (MEM with PSN and 10% FBS) except for the positive control (M+) where 0.003% of hydrogen peroxide solution was added in the culture medium. Fragments of sponges were placed in the culture medium over the cells in corresponding wells of the samples (one
fragment/well). After incubation, the solutions and samples were removed from the wells and replaced with 0.25 mg/mL of MTT solution and incubated for 3 h. Then, the solutions from the wells were replaced by isopropanol to dissolve the formazan crystals produced in the cells. The color uniformity of the solution and dissolution of all the formazan crystals were achieved by shaking on an orbital shaker for 15 min. The absorbance was determined with the spectrophotometer microplate reader Berthold Mithras LB 940 multimodal for a lamp power of 40,000 Å and a wavelength of 570 nm.

Statistical analysis. All the experiments performed on the collagen sponges studied were carried out in triplicate, and the data obtained were analyzed for statistical significance using analysis of variance (one-way ANOVA) and Tukey’s test to determine the significant differences between means. Significant differences were considered for p values < 0.05. The results were reported as samples mean ± standard deviation (SD) of independent replicates.

For cell morphology examination with an optical microscope was used. All of the chemicals needed (eosin, hematoxylin, saturated aqueous solution of picric acid, glacial acetic acid, glycerol, alum potassium, potassium iodate, PBS, deionized water, tap water, formaldehyde, calcium chloride) were obtained from Sigma-Aldrich. The steps of cell seeding and the addition of the samples after 24 h were carried out similarly to those used in the MTT method. Two pieces of sponge (5 × 5 mm²) and 1000-µL working solutions were added to each well. In the positive control well (M+), the hydrogen peroxide solution of 0.003% prepared in the culture medium was added. After 48 h, the samples from the culture plates and the culture medium maintained in an incubator in humidity conditions, at constant temperature (37 °C) were removed and washed twice with PBS. The PBS was removed, and the cells were fixed for 10 min with 1 mL of Bouin/well. Then, the Bouin solution was removed and the cells were washed three times with deionized water. After the deionized water removal, 1 mL/well of hematoxylin solution was added, left for 5–7 min, and removed, followed by two consecutive washes with running water and one wash with deionized water. The water was removed and eosin solution (1 mL/well) was added, left for 5 min, and removed. After five consecutive washes with deionized water, the plates were dried on a filter paper. Finally, the cell morphology was visualized with an optical microscope.

3. Results

3.1. Infrared Spectroscopy (IR) Measurements

To detect the specific vibrations of chemical functional groups for all the raw materials and for the collagen sponges, infrared spectroscopy was used. The IR spectra of OTC and DXC powder are presented in Figure 2, and the main IR frequencies of the functional groups are shown in Table 2.

FT-IR measurements of sponges with collagen and different concentrations of GA [30] with and without antimicrobial drug were also carried out to illustrate the chemical composition (Figure 3). All the collagen-based biomaterials prepared showed the typical absorption bands corresponding to collagen and the antimicrobial drug, as well as to the hydrogen bonds formed between the components [43]. More information [44,45] about the collagen sponges obtained can be extracted from IR spectra as follows: (a) hydrolysis degree calculated as the ratio of the band intensities $I_{\text{OH}}/I_{\text{I}}$ ($\Delta \nu_{3300\text{cm}^{-1}}/\Delta \nu_{1630\text{cm}^{-1}}$); (b) cross-linking degree obtained by the ratio of the band intensities $I_{\text{I}}/I_{\text{OH}}$ ($\Delta \nu_{1630\text{cm}^{-1}}/\Delta \nu_{3300\text{cm}^{-1}}$), high values of this ratio indicating a high cross-linking degree; (c) denaturation process evidenced by Equation (4), where $\nu_{I}$ and $\nu_{II}$ represents the wavenumbers of Amide I and Amide II, respectively; for $\Delta \nu < 100$, no distortion takes place.

$$
\Delta \nu = \nu_{I} - \nu_{II}
$$

The IR spectra interpretation [43] is highlighted in Table 3 [46].
Figure 2. The IR spectra of OTC and DXC powder.

Table 2. IR frequencies of the functional groups in OTC and DXC.

|          | OTC    |                   | DXC    |                   |
|----------|--------|-------------------|--------|-------------------|
| ν [cm⁻¹] | Functional Group | ν [cm⁻¹] | Functional Group |
| 3145     | νO-H   | 3281              | νO-H   |
| 2997     | νCH2   | 2992              | νCH2   |
| 2925     | νCH2   | 2968              | νCH2   |
| 1616     | νC=O   | 1579              | δN-H   |
| 1579     | δN-H   | 1553              | νC=O   |
| 1538     | νC=C aromatic | 1331 | δCH3   |
| 1331     | δCH3   | 1070              | νC-OH  |
| 1070     | νC-OH  |                   |        |

Figure 3. The IR spectra of collagen sponges with different GA concentrations and with antimicrobial drug (a) OTC or (b) DXC.
Table 3. Fourier transform infrared (FT-IR) spectra data of collagen sponges.

| Collagen Sponge | $\Delta A_{\text{OH}}/A_1$ | $A_1/A_{\text{OH}}$ | $\Delta \nu$ |
|-----------------|--------------------------|----------------------|-------------|
| CG:GA 0%        | 0.4111                   | 2.4326               | 84          |
| CG:OTC:GA 0%    | 0.4834                   | 2.0689               | 82          |
| CG:OTC:GA 0.25% | 0.4918                   | 2.0332               | 82          |
| CG:OTC:GA 0.5%  | 0.4551                   | 2.1973               | 86          |
| CG:OTC:GA 0.75% | 0.4484                   | 2.2301               | 81          |
| CG:OTC:GA 1%    | 0.4624                   | 2.1627               | 81          |
| CG DXC:GA 0%    | 0.4023                   | 2.4859               | 91          |
| CG:DXC:GA 0.25% | 0.4158                   | 2.4051               | 92          |
| CG:DXC:GA 0.5%  | 0.4027                   | 2.4835               | 87          |
| CG:DXC:GA 0.75% | 0.4166                   | 2.4004               | 87          |
| CG:DXC:GA 1%    | 0.3721                   | 2.6876               | 102         |

3.2. UV/Vis/NIR Spectroscopy Measurements

UV/Vis/NIR spectroscopy was used to depict the major components of the collagen-based biomaterials with antimicrobial drug and different concentrations of GA. All the sponges were scanned in reflection mode, and the UV/Vis/NIR spectra are presented in Figure 4.

![Figure 4](image-url)

Table 4 summarizes the results of the reflection UV/Vis/NIR measurements evidencing the main absorption bands specific to the raw materials, and also to the new bonds formed between components as follows: the band in the 223–313 nm domain, which is attributable to $n \rightarrow \pi^*$ of –CO–NH– from the amide structure of CG; the band corresponding to CH$_2$ in the 1181–1189-nm domain; a peak specific to $\nu_{\text{OH}}$ associated around 1500 nm; and an intense absorption peak assigned to $\delta_{\text{OH}}$ registered between 1937–1953 nm.
Table 4. UV/Vis/NIR spectra data for collagen sponges with antimicrobial drug and different GA concentrations.

| Collagen Sponge | λ_{max}, nm | Band | λ_{max}, nm | Band | λ_{max}, nm | Band | λ_{max}, nm | Band |
|-----------------|-------------|------|-------------|------|-------------|------|-------------|------|
| CG:OTC:GA 0%    | 313         |      | 1185        |      | 1492        |      | 1942        |      |
| CG:OTC:GA 0.25%| 314         |      | 1190        |      | 1495        |      | 1954        |      |
| CG:OTC:GA 0.5% | 314         |      | 1188        |      | 1496        |      | 1944        |      |
| CG:OTC:GA 0.75%| 314         |      | 1188        |      | 1501        |      | 1953        |      |
| CG:OTC:GA 1%   | 314         | -CO–NH– | 1189 | ν_{CH2} | 1497 |      | 1947        |      |
| CG:DXC:GA 0%   | 223         |      | 1183        |      | 1504        |      | 1937        |      |
| CG:DXC:GA 0.25%| 223         |      | 1183        |      | 1503        |      | 1941        |      |
| CG:DXC:GA 0.5% | 221         |      | 1181        |      | 1503        |      | 1945        |      |
| CG:DXC:GA 0.75%| 224         |      | 1183        |      | 1492        |      | 1938        |      |
| CG:DXC:GA 1%   | 223         |      | 1181        |      | 1504        |      | 1948        |      |

3.3. Swelling Capacity of the Collagen Sponges

The swelling capacity of a matrix, depending on the number of hydrophilic groups [47], is a required characteristic for biomedical applications such as dressings. Each dried collagen support was swollen in distilled water at room temperature to establish the water absorption capacity, and the standard deviations were labeled with error bars calculated from three samples. The swelling capacity of the sponges is presented in Figure 5, where the water absorption maximum for each sample is noticed. The maximum water absorption for collagen sponges with GA and OTC was recorded at 5 h, while for samples with DXC, the maximum was recorded at 4 h.

Figure 5. The swelling capacity of the CG–OTC and CG–DXC sponges with different GA concentrations.

3.4. Enzymatic Degradation

The biomaterial structural integrity is an important characteristic when its easy removal from the treated area is required. In vitro tests for the biostability of collagen-based biomaterials illustrated an improvement of their resistance to collagenase digestion due to the presence of antibiotics, and also due to the cross-linking process used in the sponges’ preparation (Figures 6 and 7).
3.5. Antimicrobial Assay

The antimicrobial susceptibility assay of oxytetracycline on the tested bacteria, MBCs of 100 μg/mL, 12.50 μg/mL, and 200 μg/mL against *Escherichia coli, Staphylococcus aureus,* and *Enterococcus faecalis,* respectively is presented in Table 5.
Table 5. Antimicrobial susceptibility of the microorganisms to oxytetracycline.

| Microorganism       | Concentration of Oxytetracycline (µg/mL) |
|---------------------|------------------------------------------|
|                     | 400 | 200 | 100 | 50  | 25  | 12.5 | 6.25 | 3.125 | 1.56 | 0.78 | 0.39 | 0.195 |
| Escherichia coli    | S   | S   | S   | S   | S   | R    | R    | R     | R    | R    | R    | R     |
| Staphylococcus aureus | S   | S   | S   | R   | R   | R    | R    | R     | R    | R    | R    | R     |
| Enterococcus faecalis | S   | S   | R   | R   | R   | R    | R    | R     | R    | R    | R    | R     |

Key: R—Resistant; S—Susceptible/Sensitivity.

In three days, the antimicrobial susceptibility was determined, and MBC values, as the average of three experiments, were reported for each isolate.

In Table 6, the results obtained for the antimicrobial susceptibility test of DXC on the selected bacteria showed MBCs of 200 µg/mL, 100 µg/mL, and 200 µg/mL against Staphylococcus aureus, Escherichia coli, and Enterococcus faecalis, respectively.

Table 6. Antimicrobial susceptibility of the microorganisms to doxycycline.

| Microorganism       | Concentration of Doxycycline, (µg/mL) |
|---------------------|--------------------------------------|
|                     | 400 | 200 | 100 | 50  | 25  | 12.5 | 6.25 | 3.125 | 1.56 | 0.78 | 0.39 | 0.195 |
| Escherichia coli    | S   | S   | S   | R   | R   | R    | R    | R     | R    | R    | R    | R     |
| Staphylococcus aureus | S   | S   | R   | R   | R   | R    | R    | R     | R    | R    | R    | R     |
| Enterococcus faecalis | S   | S   | R   | R   | R   | R    | R    | R     | R    | R    | R    | R     |

Key: R—Resistant; S—Susceptible/Sensitivity.

The inhibition percent of bacteria growth for the system with OTC is presented in Figure 8.

Figure 8. Inhibition percent of bacteria growth for the system with oxytetracycline.

The inhibition percent of bacteria growth for the doxycycline collagen sponges is shown in Figure 9.
3.6. *In Vitro Drug Release Study*

The antibiotics delivery profiles represented as cumulative drug-released percentage versus time are presented in Figure 10 for CG–OTC and in Figure 11 for CG–DXC.
To evaluate the kinetics of drug release as a function of cross-linking agent concentration, the experimental data are presented in Tables 7 and 8.

**Table 7.** Correlation coefficients for Higuchi, zero-order, and power law kinetic models; kinetic parameters specific to the power law model and cumulative oxytetracycline released percentage.

| Collagen Sponges | R (Higuchi Model) | R (Zero-Order Model) | R (Power Law Model) | Release Exponent | Kinetic Constant (1/min^n) | OTC Released Percentage (%) |
|------------------|-------------------|----------------------|---------------------|-----------------|---------------------------|-----------------------------|
| CG:OTC:GA 0%     | 0.9531            | 0.8445               | 0.9948              | 0.267           | 0.143                     | 75.83                       |
| CG:OTC:GA 0.25%  | 0.9524            | 0.8438               | 0.9943              | 0.267           | 0.135                     | 71.59                       |
| CG:OTC:GA 0.5%   | 0.9564            | 0.8496               | 0.9938              | 0.279           | 0.119                     | 67.81                       |
| CG:OTC:GA 0.75%  | 0.9594            | 0.8551               | 0.9945              | 0.283           | 0.107                     | 62.57                       |
| CG:OTC:GA 1%     | 0.9512            | 0.8394               | 0.9879              | 0.288           | 0.095                     | 56.59                       |

**Table 8.** Correlation coefficients for Higuchi, zero-order, and power law kinetic models; kinetic parameters specific to the power law model and cumulative doxycycline released percentage.

| Collagen Sponges | R (Higuchi Model) | R (Zero-Order Model) | R (Power Law Model) | Release Exponent | Kinetic Constant (1/min^n) | DXC Released Percentage (%) |
|------------------|-------------------|----------------------|---------------------|-----------------|---------------------------|-----------------------------|
| CG:DXC:GA 0%     | 0.8784            | 0.7193               | 0.9919              | 0.181           | 0.273                     | 78.80                       |
| CG:DXC:GA 0.25%  | 0.8891            | 0.7316               | 0.9891              | 0.196           | 0.235                     | 74.07                       |
| CG:DXC:GA 0.5%   | 0.9514            | 0.8300               | 0.9966              | 0.262           | 0.148                     | 71.96                       |
| CG:DXC:GA 0.75%  | 0.9525            | 0.8300               | 0.9932              | 0.280           | 0.122                     | 65.48                       |
| CG:DXC:GA 1%     | 0.9575            | 0.8383               | 0.9865              | 0.318           | 0.093                     | 61.75                       |

### 3.7. Cytotoxic Activity

For in vitro cytotoxicity analysis, both the quantitative method by MTT test and the qualitative method for cell analysis by hematoxylin–eosin staining were used in parallel. Considering the results from the antimicrobial activity, enzymatic degradation, and swelling behavior, for the cytotoxic test, the collagen sponge containing OTC and 0.5% GA was chosen and compared with the collagen sponges non-treated or treated with GA (0% and 0.5% GA).
The cell viability was determined with Equation (5), and the results are shown in Figure 2.

\[
\% \text{ cell viability} = \frac{\text{Absorbance value sample}}{\text{Absorbance value control}} \times 100 \quad (5)
\]

4. Discussion

According to the IR data (Figure 3), the absorption band attributed to ν\textsubscript{NH\textsubscript{a}} and ν\textsubscript{OH\textsubscript{a}} at 3294 cm\textsuperscript{-1} for the sponge based just on collagen [12] is recorded at higher wavenumbers in the collagen sponges with the drug and 0.25% GA (3297 cm\textsuperscript{-1} for CG:OTC:GA 0.25%, 3300 cm\textsuperscript{-1} for CG:DXC:GA 0.25%). This shift is attributed to the association degree increasing by hydrogen bonding formed between molecules of collagen and the drug. The amide I band, recorded at 1630 cm\textsuperscript{-1} in the collagen sponge [12] and assigned to the stretching vibration of the C=O (ν\textsubscript{C=O}), is found in the sponges containing CG, the drug, and GA (CG:OTC:GA 0.5%, and CG:DXC:GA 1%) at the same wavenumbers or slightly moved to higher wavenumbers, indicating the association by hydrogen bonding, which increased in the presence of GA (1629 cm\textsuperscript{-1} for CG:OTC:GA 0.75%, 1630 cm\textsuperscript{-1} for CG:OTC:GA 1%, 1631 cm\textsuperscript{-1} for CG:OTC:GA 0.25%, CG:DXC:GA 0.5% and CG:DXC:GA 0.75%, 1632 cm\textsuperscript{-1} for CG:DXC:GA 0.25%, 1634 cm\textsuperscript{-1} for CG:OTC:GA 0.5% and CG:DXC:GA 1%). The amide II band, recorded at 1549 cm\textsuperscript{-1} in collagen sponge [12], is observed at the same wavenumbers in the sponges based on CG and OTC with or without GA. In the biomaterial with CG and DXC embedded, a wavenumber decrease was noticed (1540 cm\textsuperscript{-1} for CG:DXC:GA 0% and CG:DXC:GA 0.25%), but the addition of GA up to 0.75% determined a shift to higher wavenumbers, indicating an increase in the association by hydrogen bonding (1544 cm\textsuperscript{-1} for CG:DXC:GA 0.5% and CG:DXC:GA 0.75%). The addition of 1% GA in the collagen sponges with DXC determined a major decreasing at 1532 cm\textsuperscript{-1}, which indicates that a high concentration of GA does not lead to a good cross-linking. For all the studied sponges, C–C and C–N bonds are evidenced by the amide III band recorded at ~1337 cm\textsuperscript{-1}. Also, a C–N–C bond appeared at ~1237 cm\textsuperscript{-1}, and the absorption band specific to the stretching vibration of C–OH (ν\textsubscript{C–OH}) was recorded at the same wavenumber (1081 cm\textsuperscript{-1}) in all types of sponges with active substance and GA, even if the concentration of GA varied from 0% to 1%.

According to Table 3, the intensity ratio of the bands A\textsubscript{OH}/A\textsubscript{I} (A\textsubscript{~3300}/A\textsubscript{~1630} cm\textsuperscript{-1}) indicates that the hydrolysis degree increased by the addition of OTC, reaching a maximum for 0.25% GA, while DXC presence did not increase the hydrolysis degree.

High values for the intensity ratio of the bands A\textsubscript{I}/A\textsubscript{OH} indicate a high degree of cross-linking [46].

The results obtained for Δν (Equation (4)) suggest that the denaturation process of the α-helix chain in the collagen molecule is not present during sample preparation, except for the collagen sponge with DXC cross-linked with 1% GA, where Δν > 100. This can be explained by the high amount of GA that does not react with the collagen.

Comparing Δν value and the ratio of A\textsubscript{I}/A\textsubscript{OH} corresponding to the collagen sponge with no added GA or drug (collagen sponge CG:GA 0%) with the values of the collagen sponge with GA and with OTC or DXC, the following can be observed.

The addition of OTC into the collagen sponge composition determined a slight decrease of the cross-linking degree, but it remains over two, and as the content of GA increased, the cross-linking degree increased and, in addition, Δν decreased.

The addition of DXC led to an increased cross-linking degree, and the addition of GA also determined an increase of the cross-linking degree, but Δν increased more, over 100, for the sponge CG:DXC:GA 1%, suggesting that a denaturation process occurred.

Since the sponges obtained should have a good cross-linking degree, do not cause collagen degradation, and do not contain a high percentage of cross-linking agent, it can be concluded that the best results are registered for CG:OTC:GA 0.5%, CG:OTC:GA 0.75%, CG:DXC:GA 0.5%, and CG:DXC:GA 0.75%.
The UV/Vis/NIR spectra for collagen sponges with antimicrobial drugs, and with or without the cross-linking agent (Figure 4) and the data collected in Table 4, indicate the specific absorption bands that demonstrates the contribution of each component.

According to Figure 5, the presence of the drug determined an increase in water absorption. Also, the swelling behavior of the sponges depends on the type of antimicrobial drug. Thus, DXC led to higher values of swelling degree comparing with those obtained when OTC was used. The addition of small quantities of GA (0.25%) in collagen sponges with OTC determined an increase in water absorption, while in the case of DXC, the water absorption decreased. When GA concentration increased from 0.5% to 1% in collagen sponges with OTC, the high association degree by hydrogen bonds reduced the water absorbance, and these results were in line with those obtained from spectral analysis. A similar behavior was observed for collagen sponges with DXC with one exception for 1% GA. It should be noted that cross-linked collagen sponges with OTC added absorb less water over a longer period of time (5 h), while cross-linked collagen sponges with DXC added absorb more water in a shorter period of time (4 h).

From the enzymatic degradation point of view (Figures 6 and 7), the non-cross-linked collagen sponge with no antimicrobial drug (sponge CG:GA 0%) was totally digested after 1 h of incubation with collagenase. The non-cross-linked collagen biomaterials treated with the antimicrobial drug were completely degraded after 24 h for the sponge with DXC, and after 72 h for the sponge with OTC. The collagen sponges with the antimicrobial drug and GA were totally degraded after different intervals of time depending on the cross-linking degree. It can be noticed that for higher GA concentrations (1%), the sponge with DXC was completely digested in the first 8 h, and the sponge with OTC was completely digested in 72 h. In addition, the collagen sponges containing 0.5% or 0.75% GA and treated with DXC were degraded between 70–74% after 96 h, while the collagen sponges with 0.5% or 0.75% GA treated with OTC were degraded between 55–63% after 96 h. Total degradation for the collagen sponges with 0.5% or 0.75% GA treated with DXC or OTC was obtained after 168 h. It is known that preservation of material structural integrity is one of the main properties of the collagen biomaterials to ensure an easy removal from the treated area. Thus, the collagen degradation values revealed that for both antimicrobial drugs, the cross-linking with 0.5% GA leads to formulations that best act as inhibitors of enzymatic activity, improving the biostability of the designed sponges, and the enzymatic degradation results indicating a better inhibition of collagenase in the case of oxytetracycline for this level of glutaraldehyde.

The antimicrobial activity investigation of the tested sponges was performed on Escherichia coli, Staphylococcus aureus, and Enterococcus faecalis (Tables 5 and 6). We selected these test bacteria because in dentistry, Enterococcus faecalis has been found to be associated with chronic periodontitis [48] and failed root canal treatments involving chronic apical periodontitis [49]. At the same time, the transmission of Staphylococcus aureus in the dental setting is becoming more common [50,51]; Escherichia coli bacterium is not commonly found in root canals, but some studies found this microorganism in root canals with periapical lesions [52,53].

The results presented in Figure 8 demonstrate that in most cases for a concentration of 1% GA into the CG–OTC sponges, the inhibition percent of bacteria growth decreases. On the tested samples, the best antibacterial effect was demonstrated against Escherichia coli (Gram-negative bacterium), while the lowest was demonstrated for the bacterium Enterococcus faecalis (Gram-positive bacterium). As it is well known, Gram (+) bacterium was much more difficult to destroy due to the more complex structure of the cell wall (several layers of peptidoglycan), which is than Gram (−) bacteria whose cell wall is relatively thin and composed of a single peptidoglycan layer [54]. OTC, being a broad-spectrum antibiotic that is active against a wide variety of bacteria, works by interfering with the ability of microorganisms to produce essential proteins. Without these proteins, the microorganism cannot grow and multiply. Therefore, OTC stops the spread of the bacterial infection and the remaining bacteria are killed [5]. The results indicate that 0.5% and 0.75% GA represent the optimal content of the cross-linking agent for the CG-OTC sponges. In the case of CG-DXC sponges, the optimal...
content of GA is 1% (Figure 9). These data revealed that the new collagen sponges with OTC present a better antibacterial activity against Gram-positive and Gram-negative bacteria than systems with DXC. The action of DXC, which is also a broad-spectrum antibiotic, consists of inhibiting the synthesis of bacterial proteins by binding to the 30-S ribosomal subunit, and stops bacterial growth, giving the immune system time to kill and remove the bacteria [55].

From the antibiotics release profiles (Figures 10 and 11), both antibiotics showed similar kinetic models. In all the cases, the drug delivery process could be divided in two different stages: an initial period of rapid release corresponding to the first 60–90 min, followed by a relatively slow drug release during the next 9 h of experiments for CG–OTC sponges, and 7 h for CG–DXC sponges. These delivery patterns might be due to the immediate desorption of the free drug non-entrapped in the spongious matrices, followed by a reduced release through diffusion of the antibiotic retained in the polymer matrix after gradual release medium penetration in the sponge structure [31]. The aforesaid drug-release characteristics are desired for both prophylactic and treatment of an infection associated with different dental procedures when it is necessary to achieve a high antibiotic concentration in a short period of time, followed by a sustained release to avoid further bacterial invasion or proliferation [56].

For both antibiotics, the burst release effect is more pronounced for smaller concentrations of GA. In the case of sponges with OTC, the drug-released percentage in the first 90 min is 50.07% for CG:OTC:GA 0% and 47.65% for CG:OTC:GA 0.25%, while for the sponges with DXC, the drug released percentage in the first 60 min is 59.62% for CG:DXC:GA 0% and 55.68% for CG:DXC:GA 0.25%. The increase of GA amount between 0.50–1.00% minimized the fast release of about 11.5–24.0% for CG–OTC sponges and about 24.50–38.90% for CG–DXC sponges compared to the corresponding non-cross-linked sample. It is obvious that the burst release effect is more evident for DXC-loaded collagen sponges.

After 10 h of experiments, the cumulative released percentage of OTC ranges from 56.59% to 75.83%, while for the samples with DXC, the percentage varies between 61.75–78.80% over a period of 8 h. The sponges cross-linked with 0–0.5% GA led to a higher percentage of antibiotics released in contrast with samples with a high cross-linking degree (Tables 7 and 8), with the increase being about 1.08 to 1.34 times for CG–OTC matrices, and about 1.09 to 1.27 times for CG–DXC matrices. It can be noticed that the cumulative released drug percentage in 8 h is higher for DXC-loaded collagen sponges than for OXC-loaded collagen sponges.

Also, in the case of CG–OTC sponges, the percentages of released drug were lower compared to the CG–DXC sponges cross-linked with the same amount of GA, and these results were in line with the ones obtained for the water absorption (Figure 5). The results indicate that the cross-linking degree and the type of antibiotic are the major parameters that influence the drug release kinetics from the designed sponges.

The correlation coefficient values obtained for the power law kinetic model (Equation (3)) are presented in Tables 7 and 8. These values are significantly higher than the ones obtained for its particular cases, namely the Higuchi and zero-order models. The release exponent values ranged between 0.267–0.288 for CG–OTC sponges, and from 0.181 to 0.318 for CG–DXC sponges respectively, suggest a typical non-Fickian drug-release mechanism. These results are in line with our previous works [24,30–33], which also used collagen sponges cross-linked with glutaraldehyde as carriers for different drugs, as well as with other author works [57,58].

Even if the two drugs belong to the same class of tetracycline and consequently their chemical structures are quite similar, the different behavior is attributed to the different bonds established between collagen, GA, and drugs.

Figure 12 shows that untreated or treated collagen sponges (CG:GA 0% and CG:GA 0.5% sponges) were non-cytotoxic and biocompatible, and the cell viability recording values were 118–116%, higher than that of the control culture at 24 h when cell proliferation was stimulated. After 48 h, the cell viability values of the sponges decreased to 96–93%, but with an obvious non-cytotoxic and biocompatible character. In the case of the CG:OTC:GA 0.5% sponge, compared to the control culture, the cell viability
was 83% at 24 h and 96% at 48 h. This confirms the non-cytotoxic and biocompatible nature of the CG:OTC:GA 0.5% sponge.

Hematoxylin–eosin staining carried out on cell culture is designed to help in the cell morphology interpretation obtained after the cytotoxicity experiment. Experimental observations of the cellular morphology resulting from this examination are as follows.

In the control culture well, a morphological aspect specific to the NCTC cell line with round and polygonal fibroblast cells was observed. After 48 h from seeding, the cell culture was close to the confluence (90% confluence) (Figure 13a).

When the cell culture was treated with hydrogen peroxide 0.003% (M+), a strong cytotoxic effect occurred, which led to the total destruction of the cell substrate; the attached cells are round, the cell membrane is damaged, and both the cytoplasm and intracytoplasmic granules are missing from the cell constitution (Figure 13b).
Cell cultures in contact with a non-cross-linked collagen sponge (CG:GA 0%) and with a cross-linked collagen sponge (CG:GA 0.5%) showed a specific morphology to the NCTC line; the culture was subconfluent (~80%) and the cell density was close to that of the control culture, but the cell metabolism was lower than that of the control culture. The images (Figure 13c,d) reflect the non-cytotoxic character of the sponges.

The cell culture in contact with the collagen sponges treated with GA and with OTC (CG:OTC:GA 0.5%) showed a specific morphology to the NCTC line, with round and polygonal fibroblast cells with homogeneous aspects. The cell density was close to that of the control culture, with the cell culture evolution being more advanced compared to the culture in contact with CG:GA 0% and CG:GA 0.5% sponges. The biocompatibility of the CG:OTC:GA 0.5% sponge was evident (Figure 13e).

5. Conclusions

In this paper, we presented a comparative study concerning the properties of new sponges prepared and characterized by numerous methods to provide their use as carrier supports in biomedical applications. The ability to absorb water depending on the antimicrobial drug or chemical cross-linking agent concentration is in line with the data obtained from spectral analysis. The drug release kinetics could be controlled by the cross-linking degree, with the GA concentration increase determining the decrease of the released drug percentage, and by the nature of the antibiotics, with an extended release being recorded for oxytetracycline-loaded collagen sponges. The collagen degradation values revealed that both 0.5% GA and OTC presence into the CG:OTC:GA 0.5% sponge composition ensure the best inhibitors of enzymatic activity, improving the biostability of the sponge. For this formulation, the non-cytotoxic and biocompatible nature was confirmed. Considering that a quite fast antibiotic release just after a dental procedure followed by a slower and gradual delivery during a longer period are targeted for local anti-infective dentistry therapy, the collagen sponge with 0.5% GA could be a viable topical support for oxytetracycline, with good results in the prevention/treatment of the infection at the application site, favoring tissue regeneration.

Author Contributions: Conceptualization, G.T.T., R.G.Z. and C.U.; Formal analysis, G.T.T., R.G.Z., C.U., I.R., R.C.B., M.G.A.-K., M.V.G., C.D.P.; Writing—original draft, G.T.T., R.G.Z. and C.U.; Writing—review & editing, G.T.T., R.G.Z., C.U., M.V.G.

Funding: This paper was financially supported by “Carol Davila” University of Medicine and Pharmacy through Contract No. CNFIS-FDI-2019-0534 (MEDEX-II) funded by the Ministry of National Education of Romania, from the Institutional Development Fund for Public Universities—FDI 2019.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Hleba, L.; Majerčíková, K.; Felšöcíová, S.; Andreji, J.; Fik, M.; Pavelková, A.; Kačániová, M. Antibiotic Resistance of Escherichia Coli Isolated from Intestinal Tract of Cyprinus Carpio. J. Anim. Sci. Biotechnol. 2013, 46, 133–139.
2. Nijsten, R.; London, N.; Bogaard, A.V.D.; Stobberingh, E. Antibiotic resistance among Escherichia coli isolated from faecal samples of pig farmers and pigs. J. Antimicrob. Chemother. 1996, 37, 1131–1140. [CrossRef]
3. Chopra, I.; Roberts, M. Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance. Microbiol. Mol. Biol. Rev. 2001, 65, 232–260. [CrossRef]
4. Imamura, T.; Matsushita, K.; Travis, J.; Potempa, J. Inhibition of Trypsin-Like Cysteine Proteinases (Gingipains) from Porphyromonas gingivalis by Tetracycline and Its Analogues. Antimicrob. Agents Chemother. 2001, 45, 2871–2876. [CrossRef]
5. Kowalski, C.; Pomorska, M.; Lebkowska, B.; Sławik, T. Determination of oxytetracycline in biological matrix. Acta Pol. Pharm. Drug Res. 2007, 64, 277–280.
6. Seymour, R.A.; Heasman, P.A. Pharmacological control of periodontal disease. II. Antimicrobial agents. J. Dent. 1995, 23, 5–14. [CrossRef]
7. Øyri, H.; Jonsdottir, O.; Jensen, J.L.; Bjornland, T. The use of a tetracycline drain reduces alveolar osteitis: A randomized prospective trial of third molar surgery under local anesthetics and without the use of systemic antibiotics. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2018. [CrossRef]

8. Griffin, M.O.; Ceballos, G.; Villarreal, F. Tetracycline compounds with non-antimicrobial organ protective properties: Possible mechanisms of action. Pharmacol. Res. 2011, 63, 102–107. [CrossRef]

9. Golub, L.M.; Wolff, M.; Lee, H.M.; Menamara, T.F.; Ramamurthy, N.S.; Zambon, J.; Clancio, S. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian Sources. J. Periodontal Res. 1985, 20, 12–23. [CrossRef]

10. Tiwari, G.; Tiwari, R.; Srivastava, B.; Bhati, L.; Pandey, S.; Pandey, P.; Bannerjee, S.K. Drug delivery systems: An updated review. Int. J. Pharm. Investig. 2012, 2, 2–11. [CrossRef]

11. Nitipir, C.; Albu, M.G.; Voicu, G.; Ficai, A.; Barbu, M.A.; Popa, L.G.; Minea, D.; Levai, C.; Lazar, S.; Ghica, M.V. Collagen—Vinblastine delivery systems as a new treatment for Kaposi’s Sarcoma. Rev. Chim. 2015, 66, 1169–1172.

12. Ghica, M.V.; Albu, M.G.; Kaya, D.A.; Popa, L.; Ozturk, S.; Rusu, L.-C.; Dinu-Pirvu, C.; Chelaru, C.; Albu, L.; Meghea, A.; et al. The effect of lavandula essential oils on release of niflumic acid from collagen hydrolysates. Korean J. Chem. Eng. 2016, 33, 1325–1330. [CrossRef]

13. Ungureanu, C.; Ionita, D.; Berteanu, E.; Tecaneco, L.; Zuav, A.; Demetrescu, I. Improving Natural Biopolymeric Membranes Based on Chitosan and Collagen for Biomedical Applications Introducing Silver. J. Braz. Chem. Soc. 2015, 26, 458–465. [CrossRef]

14. Liu, X.; Zheng, C.; Luo, X.; Wang, X.; Jiang, H. Recent advances of collagen-based biomaterials: Multi-hierarchical structure, modification and biomedical applications. Mater. Sci. Eng. C 2019, 99, 1509–1522. [CrossRef]

15. De Sousa, M.H.; Goisis, G. Characterization and in vitro release studies of tetracycline and rokitetracycline immobilized on anionic collagen membranes. Mater. Res. 2009, 12, 69–74.

16. Martins, V.C.; Goisis, G.; Ribeiro, A.C.; Marcantonio, E., Jr.; Bet, M.R. The controlled release of antibiotic by hydroxyapatite: Anionic collagen composites. Artif. Organs 1998, 22, 215–221. [CrossRef]

17. Rao, K.P. Recent developments of collagen-based materials for medical applications and drug delivery systems. J. Biomater. Sci. Polym. Ed. 1995, 7, 623–645.

18. Wachol-Drewek, Z.; Pfeiffer, M.; Scholl, E. Comparative investigation of drug delivery of collagen implants saturated in antibiotic solutions and a sponge containing gentamicin. Biomaterials 1996, 17, 1733–1738. [CrossRef]

19. Ruszczak, Z. Collagen as a carrier for on-site delivery of antibacterial drugs. Adv. Drug Deliv. Rev. 2003, 55, 1679–1698. [CrossRef]

20. Amruthwar, S.S.; Janorkar, A.V. In vitro evaluation of elastin-like polypeptide–collagen composite scaffold for bone tissue engineering. Dent. Mater. 2013, 29, 211–220. [CrossRef]

21. Ardelean, I.L.; Gudovan, D.; Fici, D.; Fici, A.; Androneasca, E.; Albu-Kaya, M.G.; Neacsu, P.; Ion, R.N.; Cimpean, A.; Mitran, V. Collagen/hydroxyapatite bone grafts manufactured by homogeneous/heterogeneous 3D printing. Mater. Lett. 2018, 231, 179–182. [CrossRef]

22. Weadock, K.S.; Miller, E.J.; Bellincampi, L.D.; Zawadsky, J.P.; Dunn, M.G. Physical crosslinking of collagen fibers: Comparison of ultraviolet irradiation and dehydrothermal treatment. J. Biomed. Mater. Res. 1995, 29, 1373–1379. [CrossRef]

23. Wu, X.; Black, L.; Patrick, C.W.; Santacana-Laffitte, G. Preparation and assessment of glutaraldehyde-crosslinked collagen–chitosan hydrogels for adipose tissue engineering. J. Biomed. Mater. Res. Part A 2007, 81, 59–65. [CrossRef]

24. Tihan, G.T.; Rau, I.; Zgarian, R.G.; Ghica, M.V. Collagen-based biomaterials for ibuprofen delivery. Comptes Rendus Chim. 2015, 19, 390–394. [CrossRef]

25. Reiser, K.; McCormick, R.J.; Rucker, R.B. Enzymatic and nonenzymatic cross-linking of collagen and elastin. FASEB J. 1992, 6, 2439–2449. [CrossRef]

26. García, Y.; Hemantkumar, N.; Collighan, R.; Griffin, M.; Rodriguez-Cabello, J.C.; Pandit, A. In Vitro Characterization of a Collagen Scaffold Enzymatically Cross-Linked with a Tailored Elastin-like Polymer. Tissue Eng. Part A 2009, 15, 887–899. [CrossRef]

27. Khew, S.T.; Yang, Q.J.; Tong, Y.W. Enzymatically crosslinked collagen-mimetic dendrimers that promote integrin-targeted cell adhesion. Biomaterials 2008, 29, 3034–3045. [CrossRef]
28. Sun, L.; Li, B.; Yao, D.; Song, W.; Hou, H. Effects of cross-linking on mechanical, biological and biodegradation behavior of Nile tilapia skin collagen sponge as a biomedical material. *J. Mech. Behav. Biomed. Mater.* 2018, 80, 51–58. [CrossRef]

29. Damink, L.H.H.O.; Dijkstra, P.J.; Van Luyn, M.J.A.; Van Wachem, P.B.; Nieuwenhuis, P.; Feijen, J.; Luyn, M.J.A.; Wachem, P.B. Glutaraldehyde as a crosslinking agent for collagen-based biomaterials. *J. Mater. Sci. Mater. Electron.* 1995, 6, 460–472. [CrossRef]

30. Barbaresso, R.C.; Rau, I.; Zgárian, R.G.; Meghea, A.; Ghica, M.V. Niflumic acid-collagen delivery systems used as anti-inflammatory drugs and analgesics in dentistry. *Comptes Rendus Chim.* 2014, 17, 12–17. [CrossRef]

31. Ghica, M.V.; Albu, M.G.; Popa, L.; Moisescu, S. Response surface methodology and Taguchi approach to assess the combined effect of formulation factors on minocycline delivery from collagen sponges. *Pharmazie* 2013, 68, 340–348.

32. Marin, Ş.; Albu, M.G.; Ghica, M.V.; Dinu-Pîrvu, C.; Popa, L.; Udeanu, D.I.; Mihai, G.; Enachescu, M. Collagen-Polyvinyl Alcohol-Indomethacin Biohybrid Matrices as Wound Dressing. *Pharmaceutics* 2018, 10, 224. [CrossRef]

33. Ghica, M.V.; Kaya, M.G.A.; Dinu-Pîrvu, C.-E.; Lupuleasa, D.; Udeanu, D.I.; Kaya, M.A. Development, Optimization and In Vitro/In Vivo Characterization of Collagen-Dextran Spongy Wound dressings Loaded with Flufenamic Acid. *Molecules* 2017, 22, 1552. [CrossRef]

34. Titorencu, I.; Albu, M.G.; Giurginca, M.; Jinga, V.; Antoniac, I.; Trandafir, V.; Cotrut, C.M.; Miculescu, F.; Simionescu, M.; Iulian, A. In Vitro Biocompatibility of Human Endothelial Cells with Collagen-Doxycycline Matrices. *Mol. Cryst. Liq. Cryst.* 2010, 523, 82/[654]–96/[668]. [CrossRef]

35. Payne, J.B.; Golub, L.M. Using tetracyclines to treat osteoporotic/osteopenic bone loss: From the basic science laboratory to the clinic. *Pharmacol. Res.* 2011, 63, 121–129. [CrossRef]

36. Gross, J.; Harper, E.; Harris, E.D.; McCroskery, P.A.; Highberger, J.H.; Corbett, C.; Kang, A.H. Animal collagenases: Specificity of action, and structures of the substrate cleavage site. *Biochem. Biophys. Res. Commun.* 1974, 61, 605–612. [CrossRef]

37. Albu, M.G.; Ghica, M.V. Spongious collagen-minocycline delivery systems. *Farmacia* 2015, 63, 20–25.

38. Albu, M.G.; Ghica, M.V.; Ficai, A.; Titorencu, I.; Popa, L. Influence of freeze-drying process on porosity and kinetics release of collagen-doxycycline matrices. In Proceedings of the 3rd International Conference on Advanced Materials and Systems, Bucuresti, Romania, 16–18 September 2010; Albu, L., Deselnicu, V., Eds.; INCDTP-ICPI: Bucharest, Romania, 2010; pp. 181–186.

39. Jaiswal, S.; Duffy, B.; Jaiswal, A.K.; Stobie, N.; McHale, P. Enhancement of the antibacterial properties of silver nanoparticles using β-cyclodextrin as a capping agent. *Int. J. Antimicrob. Agents* 2010, 36, 280–283. [CrossRef]

40. Tihan, G.T.; Ungureanu, C.; Barbaresso, R.C.; Zgárian, R.G.; Rau, I.; Meghea, A.; Albu, M.G.; Ghica, M.V. Chloramphenicol collagen sponges for local drug delivery in dentistry. *Comptes Rendus Chim.* 2015, 18, 986–992. [CrossRef]

41. NCCLS. *Methods for Dilution Antimicrobial Susceptibility. Test for Bacteria that Grow Aerobically*, 6th ed.; Document M7-A6; NCCLS: Wayne, PA, USA, 2003; ISBN 1-56235-486-4.

42. Hugo, W.B.; Russel, A.D. *Pharmaceutical Microbiology*, 6th ed.; Blackwell Science: London, UK, 1998.

43. Zgárian, R.G.; Tihan, G.T.; Barbaresso, R.C.; Rau, I. Spectral characterization of some collagen based composite for dental application. *UPB Sci. Bull. Ser. B* 2016, 78, 99–110.

44. Albu, M.G.; Ghica, M.V.; Giurginca, M.; Trandafir, V.; Popa, L.; Cotrut, C. Spectral characteristics and antioxidant properties of tannic acid immobilied in drug delivery systems. *Rev. Chim.* 2009, 60, 666–672.

45. Albu, M.G. *Collagen Gels and Matrices for Biomedical Applications*; Lambert Academic Publishing: Saarbrücken, Germany, 2011.

46. Andrews, M.E.; Murali, J.; Muralidharan, C.; Madhulata, W.; Jayakumar, R. Interaction of collagen with corilagin. *Colloid Polym. Sci.* 2003, 281, 766–770. [CrossRef]

47. Pal, K.; Bhandia, A.K.; Majumdar, D.K. Polymeric Hydrogels: Characterization and Biomedical Applications—A mini review. *Des. Monomers Polym.* 2009, 12, 197–220. [CrossRef]

48. Souto, R.; Colombo, A.P.V. Prevalence of Enterococcus faecalis in subgingival biofilm and saliva of subjects with chronic periodontal infection. *Arch. Oral Biol.* 2008, 53, 155–160. [CrossRef] [PubMed]

49. Love, R.M. Enterococcus faecalis—A mechanism for its role in endodontic failure. *Int. Endod. J.* 2001, 34, 399–405. [CrossRef]
50. Martin, M.V.; Hardy, P. Two cases of oral infection by methicillin-resistant Staphylococcus aureus. *Br. Dent. J.* 1991, 170, 63–64. [CrossRef]

51. Roberts, M.C.; Soge, O.O.; Horst, J.A.; Ly, K.A.; Milgrom, P. Methicillin-resistant Staphylococcus aureus from dental school clinic surfaces and students. *Am. J. Infect. Control.* 2011, 39, 628–632. [CrossRef] [PubMed]

52. Geibel, M.-A.; Schu, B.; Callaway, A.S.; Gleissner, C.; Willershausen, B. Polymerase chain reaction-based simultaneous detection of selected bacterial species associated with closed periapical lesions. *Eur. J. Med. Res.* 2005, 10, 333–338.

53. Siqueira, J.F.; Rôças, I.N.; Souto, R.; De Uzeda, M.; Colombo, A.P. Microbiological evaluation of acute periradicular abscesses by DNA-DNA hybridization. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol.* 2001, 92, 451–457. [CrossRef]

54. Walsh, F.M.; Amyes, S.G. Microbiology and drug resistance mechanisms of fully resistant pathogens. *Curr. Opin. Microbiol.* 2004, 7, 439–444. [CrossRef]

55. Maaland, M.G.; Papich, M.G.; Turnidge, J.; Guardabassi, L. Pharmacodynamics of Doxycycline and Tetracycline against Staphylococcus Pseudintermedius: Proposal of Canine-Specific Breakpoints for Doxycycline. *J. Clin. Microbiol.* 2013, 51, 3547–3554. [CrossRef] [PubMed]

56. Corobea, M.S.; Albu, M.G.; Ion, R.; Cimpean, A.; Miculescu, F.; Antoniac, I.V.; Raditoiu, V.; Sirbu, I.; Stoenescu, M.; Voicu, S.I.; et al. Modification of titanium surface with collagen and doxycycline as a new approach in dental implants. *J. Adhes. Sci. Technol.* 2015, 29, 1–14. [CrossRef]

57. Zhang, X.; Tang, K.; Zheng, X. Electrospinning and crosslinking of COL/PVA Nanofiber-microsphere Containing Salicylic Acid for Drug Delivery. *J. Bionic Eng.* 2016, 13, 143–149. [CrossRef]

58. Phaechamud, T.; Charoenteeraboon, J. Antibacterial Activity and Drug Release of Chitosan Sponge Containing Doxycycline Hyclate. *AAPS PharmSciTech* 2008, 9, 829–835. [CrossRef]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).